THQM Stock Overview
Engages in the development and manufacture of generic and in-licensed medicines in Bulgaria. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Tchaikapharma High Quality Medicines AD Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | лв17.90 |
| 52 Week High | лв18.00 |
| 52 Week Low | лв17.00 |
| Beta | 0.035 |
| 1 Month Change | 0% |
| 3 Month Change | 1.70% |
| 1 Year Change | 5.29% |
| 3 Year Change | 26.25% |
| 5 Year Change | 69.62% |
| Change since IPO | 652.27% |
Recent News & Updates
Shareholder Returns
| THQM | BG Pharmaceuticals | BG Market | |
|---|---|---|---|
| 7D | 0% | -0.1% | 0.5% |
| 1Y | 5.3% | -1.8% | 9.1% |
Return vs Industry: THQM exceeded the BG Pharmaceuticals industry which returned -1.8% over the past year.
Return vs Market: THQM underperformed the BG Market which returned 9.1% over the past year.
Price Volatility
| THQM volatility | |
|---|---|
| THQM Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 5.5% |
| Market Average Movement | 3.9% |
| 10% most volatile stocks in BG Market | 7.0% |
| 10% least volatile stocks in BG Market | 2.2% |
Stable Share Price: THQM's share price has been volatile over the past 3 months compared to the BG market.
Volatility Over Time: Insufficient data to determine THQM's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 207 | Biser Georgiev | www.tchaikapharma.com |
Tchaikapharma High Quality Medicines AD engages in the development and manufacture of generic and in-licensed medicines in Bulgaria. The company offers anaesthetic, anti-inflammatory and anti-rheumatic, antibiotic, cardiovascular system, digestive system, diabetes and metabolism, nervous system, OTC, respiratory system, oncology, and other medicines. It also provides nutritional supplements.
Tchaikapharma High Quality Medicines AD Fundamentals Summary
| THQM fundamental statistics | |
|---|---|
| Market cap | лв1.64b |
| Earnings (TTM) | лв5.04m |
| Revenue (TTM) | лв53.14m |
326.2x
P/E Ratio30.9x
P/S RatioIs THQM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| THQM income statement (TTM) | |
|---|---|
| Revenue | лв53.14m |
| Cost of Revenue | лв35.39m |
| Gross Profit | лв17.75m |
| Other Expenses | лв12.72m |
| Earnings | лв5.04m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.055 |
| Gross Margin | 33.41% |
| Net Profit Margin | 9.48% |
| Debt/Equity Ratio | 9.4% |
How did THQM perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/21 23:20 |
| End of Day Share Price | 2025/02/20 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Tchaikapharma High Quality Medicines AD is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.